CureVac has exercised its options on a selected set of potential cancer vaccine targets identified by myNEO Therapeutics under the existing partnership agreement Two option fee payments triggered to myNEO Therapeutics By applying its AI-based neoantigen discovery...
myNEO evolves into myNEO Therapeutics to reflect its new strategy to develop off-the-shelf cancer vaccine immunotherapeutics. myNEO Therapeutics to focus on building proprietary neoantigen discovery product pipeline based on a novel class of shared therapeutic cancer...
Odimma Therapeutics and myNEO Therapeutics will partner to identify personalized targets for clinical development of DNA-based cancer vaccine therapy. The myNEO Therapeutics project team is excited to have Odimma as our newest partner, and to be able to enter the...
CureVac (Nasdaq: CVAC) and myNEO Therapeutics will partner to identify novel targets for mRNA-based cancer vaccine development. We’re convinced that combining our tumor characterization and neoantigen discovery methods with an mRNA vaccination technology holds great...
Fighting Cancer with Personalized Vaccines: ONCODNA and myNEO Therapeutics collaboration OncoDNA, a company specializing in precision medicine, and myNEO Therapeutics, an AI-driven company revolutionizing neoantigen discovery within immuno-oncology, are thrilled to...
